David A. Siegel Tenaya Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 114,700 shares of TNYA stock, worth $341,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114,700
Previous 145,000
20.9%
Holding current value
$341,806
Previous $469,000
27.72%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TNYA
# of Institutions
90Shares Held
47.2MCall Options Held
35.8KPut Options Held
1.1K-
Column Group LLC San Francisco, CA9.4MShares$28 Million30.64% of portfolio
-
Casdin Capital, LLC New York, NY6.73MShares$20.1 Million2.84% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$14 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.35MShares$9.97 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$8.53 Million0.0% of portfolio
About Tenaya Therapeutics, Inc.
- Ticker TNYA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,364,700
- Market Cap $123M
- Description
- Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...